Heron Therapeutics Inc vs Progressive Corp — how do they compare? Heron Therapeutics Inc trades at $0.46 (market cap $91.46M), while Progressive Corp trades at $206 (market cap $123.39B). The key difference: Progressive Corp is far larger — about 1349.1× Heron Therapeutics Inc's market cap, and Progressive Corp pays a 6.55% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | PGR | |
|---|---|---|
Market Cap | $91.46M | $123.39B |
Sector | Health | Financials |
52-Week High | $1.96 | $252.68 |
52-Week Low | $0.39 | $190.40 |
Enterprise Value | $189.36M | $131.61B |
Dividend Yield | — | 6.55% |
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.48, up 2.06% today, with a bullish technical signal but mixed earnings performance. The company reported Q1 2026 revenue of $151M but missed EPS estimates with a $0.04 loss. Despite negative net income margins, analyst consensus remains overwhelmingly bullish with 18 buy ratings. Recent patent litigation developments and seasonal pressures have impacted quarterly results.
Outlook remains challenged by ongoing losses and competitive pressures, though strong analyst support suggests potential upside if execution improves. Key risks include patent litigation outcomes, cash flow sustainability, and ability to achieve profitability. The stock's low price presents speculative opportunity but requires careful risk management.
Progressive (PGR) trades at $205.9, down 0.99% on the day, with a bearish technical signal and neutral oscillators. The stock shows strong fundamentals with revenue growth from $49.6B in 2022 to $87.6B in 2025 and net income rising to $11.3B. Recent Q2 2026 earnings missed expectations at $4.64 EPS, but premiums and investment income remain solid. Analyst consensus is mixed with a $234.56 price target, indicating potential upside from current levels.
The outlook for PGR is cautiously optimistic given its valuation at a P/E of 10.65 and consistent profitability. Key risks include competitive pressures in auto insurance and market volatility. Investment opportunity lies in its scale and data-driven pricing, though near-term performance may hinge on earnings execution and macroeconomic factors affecting the insurance sector.
Trailing returns across standard periods
Latest headlines on both assets
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →